Clinical trials: Melanoma Stage M1
Melanoma (Skin Cancer), Melanoma Stage Stage IIIB
NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma
This study evaluates the impact of neoadjuvant Programmed cell death Protein 1 (PD-1)-based treatment regimens in patients with resectable stage IIIB-M1a cutaneous or unknown primary melanoma at high risk of relapse without…
- Conditions
- Melanoma (Skin Cancer), Melanoma Stage Stage IIIB, Melanoma Stage M1, Melanoma Stage IV
- Trial name
- NCT07740941
- Testing
- Pembrolizumab, Ipilimumab plus nivolumab
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Melanoma (Skin)
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma
RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00104897
- Testing
- tanespimycin
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- Cancer Research UK